Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review

Author:

Wu Angela12,Raack Edward J.23,Ross Colin J. D.24,Carleton Bruce C.2345

Affiliation:

1. Department of Experimental Medicine, University of British Columbia;

2. BC Children's Hospital Research Institute;

3. Department of Medical Genetics, University of British Columbia;

4. Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia; and

5. Therapeutic Evaluation Unit, Provincial Health Services Authority, Vancouver, British Columbia, Canada.

Abstract

Background: Pharmacogenetic testing in clinical settings has improved the safety and efficacy of drug treatment. There is a growing number of studies evaluating pharmacogenetic implementation and identifying barriers and facilitators. However, no review has focused on bridging the gap between identifying barriers and facilitators of testing and the clinical strategies adopted in response. This review was conducted to understand the implementation and evaluation strategies of pharmacogenetic testing programs. Methods: A PRISMA-compliant scoping review was conducted. The included studies discussed pharmacogenetic testing programs implemented in a hospital setting. Quantitative, qualitative, and mixed design methods were included. Results: A total of 232 of the 7043 articles that described clinical pharmacogenetic programs were included. The most common specialties that described pharmacogenetic implementation were psychiatry (26%) and oncology (16%), although many studies described institutional programs implemented across multiple specialties (19%). Different specialties reported different clinical outcomes, but all reported similar program performance indicators, such as test uptake and the number of times the test recommendations were followed. There were benefits and drawbacks to delivering test results through research personnel, pharmacists, and electronic alerts, but active engagement of physicians was necessary for the incorporation of pharmacogenetic results into clinical decision making. Conclusions: Further research is required on the maintenance and sustainability of pharmacogenetic testing initiatives. These findings provide an overview of the implementation and evaluation strategies of different specialties that can be used to improve pharmacogenetic testing.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference255 articles.

1. Using pharmacogenetics to improve drug safety and efficacy;Haga;JAMA,2004

2. Point-of-care provider use of pharmacogenomic (PGX) results during prescribing impacts patient (PT) recall of medication recommendations;Borden;Clin Pharmacol Ther,2017

3. Evolution of pharmacogenomics;Somogy;Proc West Pharmacol Soc,2008

4. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity;Ingelman-Sundberg;Pharmacogenomics J,2005

5. Implementation and obstacles of pharmacogenetics in clinical practice: an international survey;Abou Diwan;Br J Clin Pharmacol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3